Navigation Links
Ortho Biotech Oncology Research & Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer
Date:6/4/2009

RARITAN, N.J., June 4 /PRNewswire/ -- Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., today announced that it has entered into a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), with Steven A. Rosenberg, M.D., Ph.D., chief, Surgery Branch, serving as the NCI principal investigator, to research and develop novel cell therapy technologies as potential treatments for a variety of cancers. These adoptive immunotherapy technologies are designed to work by helping the immune system fight cancer. Standard cancer treatments still have not progressed much beyond surgery, radiation and chemotherapy, which are effective at killing tumor cells but also can harm or kill healthy tissues. Adoptive immunotherapies have the potential to spare healthy tissue because they are designed to directly find and destroy cancerous tumor cells using a patient's own immune system T cells.

Dr. Rosenberg has been a pioneer in the field of adoptive immunotherapy of cancer for decades. His group developed Tumor Infiltrating Lymphocytes (TILs), T cells obtained from a patient's tumor, expanded and then re-administered to actively seek and destroy cancer cells. Remarkable responses to this therapy have been observed in patients with malignant melanoma, a type of skin cancer that ranks sixth among U.S. men and seventh in U.S. women for the most commonly diagnosed cancer, according to the NCI. In recent years, Dr. Rosenberg's team pioneered a new technology in which T cells obtained from a patient's blood are genetically engineered to express receptors that give them specific immunity against cancer cells and then re-administered.

Researchers at Ortho Biotech Oncology Research & Development independently developed a different and proprietary adoptive immunotherapeutic approach that uses tumor antigens and other materials to stimulate T cells from a patient's blood to become Cytotoxic T Lymphocytes (CTLs), which recognize and attack tumor cells. Early clinical results show that this technology holds promise in melanoma patients and also has the potential to work in other types of cancers.

Under the CRADA, Dr. Rosenberg's lab will conduct a clinical trial in melanoma patients using Ortho Biotech Oncology Research & Development's proprietary technology. It is hoped that the technology will be effective in other types of cancer, as well. The other part of the CRADA will focus on a collaborative effort on a T-Cell Receptor (TCR) research program.

"This public-private partnership represents an extraordinary opportunity to bring together complementary and substantial expertise and resources from two groups with the common goal of advancing a highly promising new modality of therapy for patients with cancer," says Jay P. Siegel, M.D., chief biotechnology officer of Johnson & Johnson's Pharmaceuticals and Medical Devices & Diagnostics businesses.

"Dr. Rosenberg and NCI have extensive experience in the development of immunotherapies for melanoma and other cancers, as well as a strong track record in conducting early phase clinical studies. We look forward to collaborating with NCI to optimize technologies and to begin testing of our immunotherapy technology in melanoma patients by the end of 2009, with the possibility of additional studies for other types of cancer and other technologies in years to come," adds William N. Hait, M.D., Ph.D., senior vice president and worldwide head of oncology research and development, who with Dr. Siegel will direct the Ortho Biotech Oncology Research & Development team under the collaboration.

Melanoma

Skin cancer is the most common form of cancer in the United States, and Melanoma, its most deadly form, accounts for 4 percent of all diagnosed skin cancers, according to NCI. Melanoma, which usually begins in cutaneous melanocytes -- the cells that produce the pigment melanin -- is more likely to spread to other body parts, known as metastatic melanoma. In 2008 in the United States, an estimated 68,000 people were diagnosed with melanoma and 8,420 people died. The percentage of people in the United States who develop melanoma has more than doubled in the last 30 years. When detected early, melanoma can be successfully treated with surgery; however, more advanced disease has limited treatment options, with a poor prognosis. Treatment of patients with melanoma in the United States costs about $1.5 billion annually, NCI reports.

About Ortho Biotech Oncology Research & Development

Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., is a research and development organization dedicated to oncology, hematology and supportive care. It partners closely with Centocor Ortho Biotech, Inc. and Janssen-Cilag companies worldwide to bring oncology treatments and supportive medicines to patients around the world.

Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.


'/>"/>
SOURCE Ortho Biotech Oncology Research & Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Johns Hopkins University Applied Physics Lab Group Joins OrthoCare Innovations
2. Hanger Orthopedic Group, Inc. Announces Two Acquisitions Totaling $5.3 Million of Annual Net Revenue
3. Joint Replacement Consumer Awareness Campaign Endorsed by Prominent Orthopaedic Scientist
4. World-Class Pediatric Orthopaedic Clinic Now Open for Kids
5. St. Cloud Orthopedic Associates to Partner with Surgical Care Affiliates
6. Smith & Nephew Orthopaedics Announces First Contribution to OREF Grants Fund
7. OrthoSynetics Selects Landslides Sales P3 System as its Corporate Sales System
8. New Study Shows Women Experience Significantly Less Unscheduled Bleeding With the ORTHO TRI-CYCLEN(R) LO Birth Control Pill Versus Another Pill
9. American Academy of Orthopaedic Surgeons Announces Media Orthopaedic Reporting Excellence (MORE) Award Winners
10. Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 2009
11. Scientx Groupe, S.A. Appointing Spinal Orthopedic Industry Executive Oliver Burckhardt as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... MA (PRWEB) , ... July 24, 2017 , ... Every ... an invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic ... level with a James Bond theme, Mission: InstructureCon 0017. , To extend their ...
(Date:7/24/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... to expand its solution to help government contractors more quickly and cost-effectively comply with ... address the authentication requirements within NIST SP800-171, but no matter how you address ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly ... for Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... long term skin conditions, including cancer. In the short term, overexposure to ...
(Date:7/24/2017)... ... July 24, 2017 , ... Independence Blue Cross ... on an Innovation Collaboration program, have signed a five-year agreement that will marshal ... the care members and patients receive. The agreement also signifies Jefferson Health officially ...
(Date:7/24/2017)... ... ... CDC study shows that, although people are taking more steps to protect themselves from sunburn, ... one case of sunburn within the past year. It’s common and people have been dealing ... only recently have people become conscientious of the risks that accompany sunburns. , The team ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc ... completing a comprehensive review of its manufacturing network, the ... and distribution facilities in Huntsville, Alabama ... take place over the next 12 to 18 months. ... impacted by declining volumes of commoditized products and these ...
Breaking Medicine Technology: